Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

作者：Boenner G^*; Bakris G L; Sica D; Weber M A; White W B; Perez A; Cao C; Handley A; Kupfer S

来源：Journal of Human Hypertension, 2013, 27(8): 479-486.

DOI：10.1038/jhh.2013.6

• ACE inhibitor
• angiotensin receptor blocker
• azilsartan medoxomil
• drug therapy

Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-converting enzyme inhibitor ramipril (RAM) in patients with clinic systolic blood pressure (SBP) 150-180 mm Hg. Patients were randomised (n = 884) to 20 mg AZL-M or 2.5 mg RAM once daily for 2 weeks, then force-titrated to 40 or 80 mg AZL-M or 10 mg RAM for 22 weeks. The primary endpoint was change in trough, seated, clinic SBP. Mean patient age was 57 +/- 11 years, 52.4% were male, 99.5% were Caucasian. Mean baseline BP was 161.1 +/- 7.9/94.9 +/- 9.0 mm Hg. Clinic SBP decreased by 20.6 +/- 0.95 and 21.2 +/- 0.95 mm Hg with AZL-M 40 and 80 mg vs12.2 +/- 0.95 mm Hg with RAM (P%26lt;0.001 for both AZL-M doses). Adverse events leading to discontinuation were less frequent with AZL-M 40 and 80 mg (2.4% and 3.1%, respectively) than with RAM (4.8%). These data demonstrated that treatment of stage 1-2 hypertension with AZL-M was more effective than RAM and better tolerated.

• 出版日期2013-8